SYRS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 112753 min ago

@ $7.03

Išleistas: 14 vas. 2024 @ 16:30

Grąža: -26.03%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 3.84 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines...

Stats
Šios dienos apimtis	301 204
Vidutinė apimtis	204 675
Rinkos kapitalizacija	138.99M
EPS	$0 ( 2024-03-27 )
Kita pelno data	( $-0.890 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.900
ATR14	$0.0170 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Roth David	Sell	10 451	Common Stock
2024-03-31	Stephens Kristin	Buy	11 666	Common Stock
2024-04-01	Stephens Kristin	Sell	4 218	Common Stock
2024-03-31	Stephens Kristin	Sell	11 666	Restricted Stock Units
2024-03-31	Stephens Kristin	Buy	2 000	Common Stock

INSIDER POWER
54.69
Last 100 transactions
Buy: 2 824 203 \| Sell: 497 307

Tūris Koreliacija

Ilgas: -0.09 (neutral)

Trumpas: -0.88 (strong negative)

Signal:(23.582) Be Aware. Possible trading coming up! (swing)

Syros Pharmaceuticals Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Syros Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos

0.80
( moderate )

0.79
( moderate )

0.00
( neutral )

0.69
( moderate )

-0.37
( neutral )

-0.57
( weak negative )

Syros Pharmaceuticals Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$9.94M
Bruto pelnas:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2023
Pajamos:	$9.94M
Bruto pelnas:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2022
Pajamos:	$14.88M
Bruto pelnas:	$11.91M (80.06 %)
EPS:	$-3.90

FY	2021
Pajamos:	$23.49M
Bruto pelnas:	$23.49M (100.00 %)
EPS:	$-18.80

Financial Reports:

No articles found.

Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.